William Schary

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 327 citations

Medicine, Hematology, Immunology +15

Warfarin STEREOCHEMICAL ASPECTS OF ITS METABOLISM AND THE INTERACTION WITH PHENYLBUTAZONE

Richard J. Lewis, William Trager, Kenneth K. Chan et al. · Journal of Clinical Investigation · 1974 · 284 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

Michele C. Meyer, Arthur B. Straughn, Ming Lo et al. · PubMed · 1984 · 167 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Eugen Tausch, Christof Schneider, Sandra Robrecht et al. · Blood · 2020 · 127 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation

William Schary, Malcolm Rowland · Journal of Pharmacokinetics and Biopharmaceutics · 1983 · 51 citations

Pharmacy, Pharmacokinetics, Pharmacology +16